David A. Siegel Xeris Biopharma Holdings, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$1.7 - $2.45 $22,885 - $32,981
13,462 Added 133.33%
23,559 $53,000
Q1 2024

May 15, 2024
BUY
$2.04 - $3.22 $20,597 - $32,512
10,097 New
10,097 $22,000
Q3 2022

Nov 14, 2022
SELL
$1.37 - $1.93 $59,869 - $84,341
-43,700 Reduced 66.41%
22,100 $34,000
Q2 2022

Aug 15, 2022
BUY
$1.48 - $2.64 $78,292 - $139,656
52,900 Added 410.08%
65,800 $101,000
Q1 2022

May 16, 2022
BUY
$2.0 - $2.87 $25,800 - $37,023
12,900 New
12,900 $33,000

Others Institutions Holding XERS

# of Institutions
141
Shares Held
59.9M
Call Options Held
148K
Put Options Held
45.7K
View Full List

About Xeris Biopharma Holdings, Inc.

XERS Quotes by TradingView
  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $397M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email